ライフサイエンスコーパス: marimastat

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 e (AUC) tended to correlate with the dose of Marimastat.

2 -free form and in complex with the inhibitor marimastat.

3 ially inhibited by the hydroxamate inhibitor Marimastat.

4 effect that was blocked by the MMP inhibitor marimastat.

5 ients were randomly assigned to receive oral marimastat (10 mg bid; n = 114) or a placebo (n = 65) wi

6 1-year survival rate for patients receiving marimastat 25 mg was similar to that of patients receivi

7 etween patients treated with gemcitabine and marimastat 5 and 10 mg (P <.003).

8 pancreatic cancer were randomized to receive marimastat 5, 10, or 25 mg bid or gemcitabine 1,000 mg/m

9 ignificantly less efficient (>100-fold) than marimastat, a broad-spectrum MMP inhibitor, in enhancing

10 Plasma concentrations of Marimastat achieved at dose levels 2 and 3 (50 mg and 10

11 Intracameral injection of Marimastat also suppressed basic fibroblast growth facto

12 e required for intravasation by showing that marimastat, an inhibitor of MMPs, reduced intravasation

13 rence in survival between 5, 10, or 25 mg of marimastat and gemcitabine (P =.19).

14 In view of the manageable tolerability of marimastat and its ease of administration, further studi

15 talytic domain in complex with the inhibitor marimastat and the inhibitor-free form.

16 on of sVR-1 breakdown with the MMP inhibitor marimastat, and the provision of exogenous recombinant s

17 he following synthetic MMPIs: batimastat and marimastat (BB-94 and BB-2516, respectively, British Bio

18 and pharmacokinetics of escalating doses of Marimastat (British Biotech, Inc, Oxford, United Kingdom

19 Marimastat does not prolong PFS when used after first-li

20 Combining Wf-536 with the MMP inhibitor Marimastat greatly enhanced in vitro inhibition of endot

21 tudy provide evidence of a dose response for marimastat in patients with advanced pancreatic cancer.

22 Patients with higher marimastat levels exhibited MST, and MST was associated

23 Z and the matrix metalloproteinase inhibitor marimastat (MRM) in patients with recurrent GBM was stud

24 10-30 mg of the broad-spectrum MMP inhibitor marimastat over a 2-week period via surgically implanted

25 loskeletal toxicity was severe in only 8% of marimastat patients).

26 ty of marimastat was musculoskeletal (44% of marimastat patients, compared with 12% of gemcitabine pa

27 In addition, patients who had a marimastat plasma concentration of at least 10 ng/mL at

28 I clinical trials initiated in 1997-98 using marimastat, prinomastat (AG3340), and BAY 12-9566 alone

29 ancreatic cancer performed to date, compares marimastat, the first of a new class of agents, with gem

30 When comparing placebo with marimastat, there was no significant difference in PFS (

31 orted in 22% and 12% of the gemcitabine- and marimastat-treated patients, respectively.

32 Histologically, marimastat-treated rat joints were characterized by soft

33 Marimastat-treated rats exhibited various clinical signs

34 he estimated plasma elimination half-life of Marimastat was 4 to 5 hours.

35 Marimastat was administered orally at 25, 50, or 100 mg

36 The major toxicity of marimastat was musculoskeletal (44% of marimastat patien

37 Marimastat was well absorbed from the gastrointestinal t

38 Patients treated with marimastat were more likely to develop grade 2 or 3 musc

39 the broad spectrum metalloprotease inhibitor marimastat, were independently bound to the catalytic do

40 -spectrum matrix metalloproteinase inhibitor Marimastat, which may result from decreased N-cadherin s

41 PC3 cells with a combination of Wf-536 plus Marimastat with or without Paclitaxel, significantly inh

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。